目的：研究lncRNA SNHG10和甲基转移酶METTL3在结直肠癌(CRC)组织和癌旁组织中表达情况。探讨lncRNA SNHG10与METTL3在CRC中潜在联系。方法：收集15例CRC患者的肿瘤组织和癌旁组织样本。采用生物信息学方法、实时荧光定量PCR(RT-qPCR)和免疫印迹法(Western blot)探究CRC中lncRNA SNHG10、METTL3表达情况。分析lncRNA SNHG10在结直肠癌中的相对表达水平与预后的关系。通过TCGA数据库、ENCORI、cBioPortal网站及结肠癌细胞系(HCT116)体外抑制实验分析基因相互作用。结果：生物信息学网站和RT-qPCR实验显示lncRNA SNHG10在结直肠癌中比癌旁组织表达上调(P＜0.05)。lncRNA SNHG10的高表达预示着CRC患者易发生淋巴结转移,且疾病特异性生存率和总生存率相对较低(P＜0.05)。RT-qPCR和 Western blot实验结果证实METTL3在CRC肿瘤组织中高表达。体外实验显示,HCT116细胞中敲减lncRNA SNHG10导致METTL3在mRNA和蛋白水平表达均下调(P＜0.05)。结论：lncRNA SNHG10的高表达与肿瘤进展及预后较差相关。lncRNA SNHG10与METTL3存在正相关关系,并调控METTL3表达。本研究提示SNHG10可能是一种有前途的CRC生物标志物和治疗靶点。
Objective: To study the expression of lncRNA SNHG10 and methyltransferase METTL3 in colorectal cancer (CRC) tissues and adjacent tissues. Meanwhile, to explore the potential relationship between lncRNA SNHG10 and METTL3 in CRC. Methods: Tumor tissue and paracancerous tissue samples of 15 CRC patients were collected. The expression of lncRNA SNHG10 and METTL3 in CRC was investigated by bioinformatics, real-time fluorescence quantitative PCR (RT-qPCR) and Western blot. The relationship between the relative expression level of lncRNA SNHG10 in colorectal cancer and prognosis was analyzed. The gene interaction was analyzed by TCGA database, ENCORI, cBioPortal website and in vitro inhibition experiment of colon cancer cell line (HCT116). Results: Bioinformatics website and RT-qPCR experiments showed that lncRNA SNHG10 was up-regulated in colorectal cancer compared with adjacent tissues (P＜0.05). The high expression of lncRNA SNHG10 indicated that CRC patients were more likely to have lymph node metastasis, and the disease-specific survival rate and overall survival rate were relatively low (P＜0.05). RT-qPCR and Western blot results confirmed that METTL3 was highly expressed in CRC tumor tissues. In vitro experiments showed that knockdown of lncRNA SNHG10 in HCT116 cells resulted in down-regulation of METTL3 expression at both mRNA and protein levels (P＜0.05). Conclusion: The high expression of lncRNA SNHG10 is associated with tumor progression and poor prognosis. LncRNA SNHG10 is positively correlated with METTL3 and regulates METTL3 expression. This study suggests that SNHG10 may be a promising CRC biomarker and therapeutic target.
[1] Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040[J]. Transl Oncol,2021,14(10):101174.
[2] Brody H. Colorectal cancer[J]. Nature,2015,521(7551):S1.
[3] Wei W, Zeng H, Zheng R, et al. Cancer registration in China and its role in cancer prevention and control[J]. Lancet Oncol, 2020,21(7):e342-e349.
[4] Li C, Sun YD, Yu GY, et al. Integrated omics of metastatic colorectal cancer[J]. Cancer Cell, 2020,38:734-47. e9.
[5] Bridges MC, Daulagala AC, Kourtidis A. LNCcation: lncRNA localization and function[J]. J Cell Biol,2021,220(2):e202009045.
[6] Lan T, Yuan K, Yan X, et al. LncRNA SNHG10 Facilitates Hepatocarcinogenesis and Metastasis by Modulating Its Homolog SCARNA13 via a Positive Feedback Loop[J]. Cancer Res, 2019,79(13):3220-3234.
[7] Zhang Y, Guo H, Zhang H. SNHG10/DDX54/PBX3 Feedback Loop Contributes to Gastric Cancer Cell Growth[J]. Dig Dis Sci,2021,66(6):1875-1884.
[8] Lv W, Jia Y, Wang J, et al. Long non-coding RNA SNHG10 upregulates BIN1 to suppress the tumorigenesis and epithelial-mesenchymal transition of epithelial ovarian cancer via sponging miR-200a-3p[J]. Cell Death Discov,2022,8(1):60.
[9] Aini S, Bolati S, Ding W, et al. LncRNA SNHG10 suppresses the development of doxorubicin resistance by downregulating miR-302b in triple-negative breast cancer[J]. Bioengineered,2022,13(5):11430-11439.
[10] Chan JJ, Tay Y. Noncoding RNA:RNA regulatory networks in cancer[J]. Int J Mol Sci,2018,19:1310.
[11] Yuan X, Yang T, Xu Y, et al. SNHG10 Promotes Cell Proliferation and Migration in Gastric Cancer by Targeting miR-495-3p/CTNNB1 Axis[J]. Dig Dis Sci,2021,66(8):2627-2636.
[12] Wei Y, Li Y, Lu C. Exploring the role of m6A modification in cancer[J]. Proteomics,2023,23(13-14):e2200208.
[13] Xu Y, Bao Y, Qiu G, et al. METTL3 promotes proliferation and migration of colorectal cancer cells by increasing SNHG1 stability[J]. Mol Med Rep,2023,28(5):217.
[14] Li H, Liu Z, Wang H. Expression and clinical significance of METTL3 in colorectal cancer[J]. Medicine (Baltimore),2023,102(37):e34658.
[15] Zhang H, Fang Z, Guo Y, et al. Long noncoding RNA SNHG10 promotes colorectal cancer cells malignant progression by targeting miR-3690[J]. Bioengineered,2021,12(1):6010-6020.
[16] Huang Y, Luo Y, Ou W, et al. Exosomal lncRNA SNHG10 derived from colorectal cancer cells suppresses natural killer cell cytotoxicity by upregulating INHBC [J]. Cancer Cell Int,2021,21(1):528.
[17] Chen H, Gao S, Liu W, et al. RNA N6-Methyladenosine Methyltransferase METTL3 Facilitates Colorectal Cancer by Activating the m6A-GLUT1-mTORC1 Axis and Is a Therapeutic Target [J].Gastroenterology,2021,160(4):1284-1300.e16.
[18] Wei X, Huo Y, Pi J, et al. METTL3 preferentially enhances non-m6A translation of epigenetic factors and promotes tumourigenesis[J]. Nat Cell Biol,2022,24(8):1278-1290.
[19] Yankova E, Blackaby W, Albertella M, et al. Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia[J]. Nature,2021,593(7860):597-601.
[20] Pan J, Liu F, Xiao X, et al. METTL3 promotes colorectal carcinoma progression by regulating the m6A-CRB3-Hippo axis[J]. J Exp Clin Cancer Res,2022,41(1):19.
